Home›People›Jared Cumming
Jared Cumming

Jared Cumming

Chief scientific officer at Matchpoint Therapeutics and Atlas Venture advisor.

Executive
Updated Nov 20, 2026·Latest SEC filing Nov 20, 2026·Suggest an edit

About Jared Cumming

Jared Cumming is chief scientific officer at Matchpoint Therapeutics. Matchpoint develops covalent small-molecule medicines for immune diseases. He also serves as an Atlas Venture advisor. Atlas Venture builds biotechnology companies.

Before Matchpoint, he was senior vice president of drug discovery at LifeMine Therapeutics, where he worked on fungal natural products. Earlier, he held increasingly senior roles at Merck and Schering-Plough across neuroscience, immuno-oncology and oncology. He helped advance seven compounds into clinical trials. Ulevostinag reached Phase 2 in immuno-oncology, while verubecestat reached Phase 3 in Alzheimer’s disease. He has contributed to more than 110 patents and publications. He holds a chemistry doctorate from Johns Hopkins University and a chemistry bachelor’s degree from Williams College.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Jared Cumming in the role, so the role may have started earlier or lasted longer.

Matchpoint Therapeutics Inc. Current
Chief Scientific Officer
2026 – Present · Watertown, MA
Matchpoint develops oral drugs that bind hard-to-treat protein targets in immune diseases.
Atlas Venture Current
Atlas Advisor
LifeMine Therapeutics
SVP, Drug Discovery
Merck
Schering-Plough

Key Colleagues at Startups

The people Jared Cumming works with at each company, as listed on that company's latest Form D.

Matchpoint Therapeutics Inc. · Form D, Nov 20, 2026
Andre Turenne
Andre Turenne
Director; President & Chief Executive Officer
BM
Brian Matesic
Director; Principal, Norwest
KP
Kanishka Pothula
Director; Managing Partner, Nextech
JH
Jason Hafler
Director; Managing Director, Sanofi Ventures
BB
Bruce Booth
Chairman; Partner, Atlas Venture
DB
Daniel Becker
Director; Managing Director, Access Biotechnology
DN
John O'Malley
John O'Malley
Chief Medical Officer

Sources

  1. SECMatchpoint Therapeutics Inc. Form D, filed Nov 20, 2026